Eye Tracking Study of Attention and Reward in Adults With Bipolar Disorder
Uses eye-tracking technology to study attention and reward response in adults with bipolar disorder.
Key facts
- Who runs it
- University Hospitals Cleveland Medical Center
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 27 Mar 2019
- Expected to end
- 1 Apr 2027
- Type of study
- Observational, 5 groups
- Treatments tested
- Eye tracking
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bipolar disorder, with or without anxiety or substance use disorder, and also healthy volunteers. It uses eye tracking to study attention, reward and thinking control.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Bipolar I or II disorder, currently in a depressive episode or in remission from a mood episode. Young Mania Rating Scale score of 8 or less. Four groups: no anxiety or substance use disorder; anxiety disorder (Hamilton Anxiety score 18 or more); anxiety plus substance use disorder; substance use disorder without anxiety (Hamilton Anxiety score 12 or less).
- Earlier treatment
- Must take psychiatric medicines as the investigator decides. Cannot have had electroconvulsive therapy (ECT) in the last 6 months (bipolar groups).
Main reasons for not taking part
- Significant structural brain lesion or progressive neurological disease
- Currently pregnant or planning to become pregnant
- Current antisocial or borderline personality disorder (bipolar groups); OCD, PTSD or ADHD in the anxiety groups
- Taking steroids, stimulants or opioid painkillers (some groups)
- Nicotine use disorder or any nicotine use within a week before the eye tracking visit
The registry criteria, word for word
Show all 5 criteriaShow less
Other criteria
- Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder; Inclusion Criteria for Group 1:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 1:; Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had electroconvulsive therapy (ECT) treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia); Inclusion Criteria for Group 2:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI); Hamilton Anxiety Rating Scale total score ≥ 18; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 2:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder; Inclusion Criteria for Group 3:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Meets diagnostic criteria for a substance use disorder within the last 3 months; Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI); Currently in a depressive episode or currently in remission from a mood episode; Hamilton Anxiety Rating Scale total score ≥ 18; Young Mania Rating Scale total score ≤ 8; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 3:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Intoxicated or in acute withdrawal state; Currently pregnant or planning to become pregnant; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder; Inclusion Criteria for Group 4:; Male or female, age 18 or older; Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI); Meets diagnostic criteria for a substance use disorder within the last 3 months; Currently in a depressive episode or currently in remission from a mood episode; Young Mania Rating Scale total score ≤ 8; Hamilton Anxiety Rating Scale total score ≤ 12; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Subject is compliant with taking psychiatric medication(s) per the investigator's discretion; Exclusion Criteria for Group 4:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD); Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment; Intoxicated or in an acute withdrawal state; Currently pregnant or planning to become pregnant; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit; Has had ECT treatment within the last 6 months
- Inclusion and exclusion criteria for Group 5: Healthy Volunteers; Inclusion criteria for Group 5:; Male or female, age 18 or older; In the opinion of the investigator, capable of understanding and complying with protocol requirements; In the opinion of the investigator, has the competency to understand and sign the informed consent; Physically healthy as determined by research psychiatrist; Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI); Exclusion Criteria for Group 5:; Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis); Progressive neurological disease such as neurodegenerative disease; Any psychiatric disorder including any severe personality disorder; Currently pregnant or planning to become pregnant; Tests positive for illegal substances or prescription medications for which they do not have a valid prescription; Currently taking any steroids, stimulants, or opioid pain killers; Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit
Where in United States
- University Hospitals Cleveland Medical Center - Mood Disorders ProgramCleveland, United StatesContact: Nicole Jones, MATaking people
About the trial
What the trial wants to find out
The purpose of this study is to use eye-tracking technology to study attentional biases, reward sensitivity, and cognitive control in adult patients with bipolar disorder with or without anxiety and/or substance use disorder comorbidity.
The 5 groups in the trial
- Bipolar without Anxiety or Substance Use Disorder
Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
Treatment: Eye tracking
- Bipolar disorder with a current anxiety disorder only
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
Treatment: Eye tracking
- Bipolar disorder with a current anxiety disorder and a current
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
Treatment: Eye tracking
- Bipolar disorder with a current substance use disorder only
Subjects who are diagnosed with bipolar disorder \& a substance use disorders but not a current anxiety disorder
Treatment: Eye tracking
- Healthy Volunteers
Treatment: Eye tracking
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder and Different Psychiatric Comorbidities: An Eye-Tracking Study
- Plain-language title
- Eye Tracking Study of Attention and Reward in Adults With Bipolar DisorderGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 October 2026